Tempol

DRUG6 trials

Sponsors

National Cancer Institute (NCI), Matrix Biomed, Inc., The University of Texas at Arlington, Adamis Pharmaceuticals Corporation, University of Georgia

Conditions

Anal CancerCardiovascular DiseasesCardiovascular Risk FactorCovid19HealthyMetastatic CancerMucositisNephrotoxicity

Phase 1

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

TerminatedNCT01324141

National Cancer Institute (NCI)Anal Cancer

Start: 2011-03-18End: 2015-04-15Updated: 2021-11-23

The Effect of Antioxidants on Skin Blood Flow During Local Heating

CompletedNCT03680638

The University of Texas at ArlingtonCardiovascular Diseases, Cardiovascular Risk Factor, Vasodilation

Start: 2016-09-07End: 2017-10-09Updated: 2018-09-21

Phase 2

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

RecruitingNCT03480971

Matrix Biomed, Inc.Mucositis, Nephrotoxicity, Ototoxicity

Start: 2019-05-13End: 2025-12-31Target: 120Updated: 2024-11-20

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

TerminatedNCT04729595

Adamis Pharmaceuticals CorporationCovid19

Start: 2021-09-01End: 2022-09-21Updated: 2022-12-06

Effects of an Antioxidant Supplement on Blood Vessel Health

RecruitingNCT06424756

University of GeorgiaHealthy

Start: 2024-07-01End: 2030-03-31Target: 60Updated: 2024-12-09

Unknown Phase

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.Metastatic Cancer

Updated: 2022-09-01